Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/50104| Title: | Monoclonal antibody therapy in cystic fibrosis and asthma. | Authors: | Vu H.D.;Shafuddin E.;Willis J.;Pallin M. ;Armstrong D. ;Daley C. | Monash Health Department(s): | Respiratory and Sleep Medicine | Institution: | (Vu, Shafuddin, Willis, Pallin, Armstrong, Daley) Monash Lung Sleep Allergy & Immunology, Monash Medical Centre, Melbourne, VIC, Australia (Shafuddin) Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand |
Issue Date: | 28-Jul-2023 | Copyright year: | 2023 | Publisher: | John Wiley and Sons Inc | Place of publication: | Australia | Publication information: | Respirology. 28(6) (pp 571-574), 2023. Date of Publication: June 2023. | Journal: | Respirology | DOI: | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1111/resp.14498 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/50104 | Type: | Letter | Subjects: | asthma bronchiectasis cystic fibrosis lower respiratory tract infection osteoporosis Pseudomonas aeruginosa respiratory tract inflammation Staphylococcus aureus urticaria azithromycin benralizumab corticosteroid cystic fibrosis transmembrane conductance regulator immunoglobulin E mepolizumab monoclonal antibody omalizumab |
Type of Clinical Study or Trial: | Opinion, perspective or news |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.